| Literature DB >> 27503759 |
Danli Wang1,2, Ping Lu1, Yang Liu1, Li Chen1, Rui Zhang1, Weihao Sui1, Alexandru George Dumitru1, Xiaowen Chen3, Feiqiu Wen3, Hong-Wei Ouyang1,4, Junfeng Ji1,4.
Abstract
Cellular senescence plays an important role in diverse biological processes such as tumorigenesis and organismal aging. However, lack of methods to specifically identify and isolate live senescent cells hampers the precise understanding of the molecular mechanisms regulating cellular senescence. Here, we report that utilization of fluorescent ubiquitination-based cell cycle indicator (FUCCI) technology allows isolation of live premature senescent cells induced by doxorubicin treatment. Exposure of human foreskin fibroblasts (HFFs) to a low dose of doxorubicin led to cellular senescent phenotypes including formation of γ-H2AX and 53BP1 foci indicative of DNA damage, decreased cell proliferation and increased senescence-associated β-galactosidase (SA-β-gal) activity. Importantly, doxorubicin-induced senescent cells were arrested at S/G2/M phases of cell cycle which can be reported by a construct encoding a fragment of hGeminin fused with monomeric Azami-Green (mAG-hGeminin). Flow cytometric sorting of GFP(+) cells from doxorubicin-treated HFFs carrying mAG-hGeminin reporter enabled isolation and enrichment of live senescent cells in the culture. Our study develops a novel method to identify and isolate live premature senescent cells, thereby providing a new tool to study cellular senescence.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27503759 PMCID: PMC4977570 DOI: 10.1038/srep30705
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Doxorubicin treatment induced premature senescence of HFFs.
(A) Left, control HFFs and HFFs treated with doxorubicin for 4 days were stained with by γ-H2AX and 53BP1 antibodies, respectively. Right, the percentages of γ-H2AX and 53BP1 positive cells were quantified (**p < 0.01, t-test, n = 3). Scale bar: 50 μm. Cells in the inserts of the images were shown by arrows. (B) Left, SA-β-gal staining was performed on control HFFs and HFFs after 4 days of doxorubicin treatment. Right, the percentages of SA-β-gal positive cells were quantified (**P < 0.01, t-test, n = 3). Scale bar: 200 μm. (C) Left, Ki67 staining was performed on control HFFs and HFFs after 4 days of doxorubicin treatment. Right, the percentages of Ki67 positive cells were quantified (**p < 0.01, t-test, n = 3). Scale bar: 100 μm. (D) Control HFFs and HFFs after 4 and 8 days of doxorubicin treatment were performed with flow cytometry analysis. The fractions of cells at G1, S and G2 phases were quantified (n = 3).
Figure 2Isolation of live premature senescent HFFs carrying mAG-hGeminin reporter.
(A) Left, SA-β-gal staining of GFP+ and GFP− cells sorted from HFFs carrying mAG-hGeminin reporter at day 8 of doxorubicin treatment. Right, the percentages of SA-β-gal positive cells were quantified (**P < 0.01, t-test, n = 3). Scale bar: 200 μm. (B) Growth curve analysis of GFP+ and GFP− cells sorted from HFF cells carrying mAG-hGeminin reporter at day 8 of treatment with or without 100 ng/ml doxorubicin. Cells were seeded into 12-well plates and counted at the indicated days. Long-term cumulative population doubling was determined by passaging cells every 3 days. Population doublings were calculated at different passages and plotted. The p values between Control/GFP+ and Doxorubicin/GFP+ were <0.01 at all days examined except at day 3 (p = 0.0475, t-test, n = 3). The p values between Control/GFP− and Doxorubicin/GFP− were all <0.01 except on day 3 (p = 0.07, t-test, n = 3). (C) Left, GFP+ and GFP− cells sorted from HFFs carrying mAG-hGeminin reporter at day 8 of doxorubicin treatment were stained with by γ-H2AX antibody. Right, the percentages of γ-H2AX positive cells were quantified (**p < 0.01, t-test, n = 3). Scale bar: 30 μm. (D) Left, GFP− and GFP− cells sorted from HFFs carrying mAG-hGeminin reporter at day 8 of doxorubicin treatment were stained with by 53BP1 antibody. Right, the percentages of 53BP1 positive cells were quantified (**p < 0.01, t-test, n = 3). Scale bar: 30 μm. (E) Left, GFP+ and GFP− cells sorted from HFFs carrying mAG-hGeminin reporter at day 8 of doxorubicin treatment were stained with by Ki67 antibody. Right, the percentages of Ki67 positive cells were quantified (**p < 0.01, t-test, n = 3). Scale bar: 50 μm.